# Pediatrix Medical Group, Inc. (MD) · Edgar & Edgarette company card

> Pediatrix Medical Group (MD) saw revenue fall 4.9% in FY2025 to $1.9 billion, operating margin 10.9% against a 2.0% median for hospitals, equity 38.5% of assets. Every figure is from the company’s own annual report filed with the SEC.

SEC CIK 893949 · fiscal year ended 2025-12-31 · 5 audited years read · [page](https://www.pops4.com/boards/company/MD) · [JSON](https://www.pops4.com/boards/company/MD.json)

## Figures, as filed in the 10-K

| Measure | Value |
|---|---|
| Revenue | $1.9B |
| Revenue growth, 1 year | -4.9% |
| Revenue growth per year | 0.0% |
| Operating margin | 10.9% (prior year -3.4%) |
| Net margin | 8.6% |
| Operating cash flow | $271M |
| Capital spending | — |
| Free cash flow | — |
| Cash | $375M |
| Long-term debt | $597M |
| Total assets | $2.2B |
| Total equity | $866M |
| Equity ÷ assets | 38.5% |
| Return on equity | 19.1% |
| Dividend per share | — |
| Dividend years rising | — |

## Readings, computed from those figures

- Altman Z: 2.05 (grey zone)
- Piotroski F: 6 of 9 (solid)
- Health Harbor boat: New ship · no warning signs
- Cash Compass: In between · no clear cash pattern yet

## Edgarette's reading

Exposure: revenue $1.9B (FY2025), total debt $597.3M. Experience: revenue down 4.9% on the year, up 0.0% a year over 4 years; operating margin 10.9%, up from -3.4%. Soundness: equity 38.5% of assets, return on equity 19.1%. Credibility: four or more audited years, reasonable weight. Range: 80% of past cases like this landed between $1.7B and $2.0B next year (method v4.1: its own 4-year record of growth weighed at 50% against $1B–10B filers; across 2019–2025, 69.0% landed inside, 83.4% on the one year the method never saw). In a shock year the stress range is $1.5B to $2.1B. A statistical range, not company guidance. Against peers (54 filers, $50M+ revenue, its industry group): operating margin 10.9% against a 2.0% median; growth -4.9% against 13.0%.

Range logged 2026-11-01, receipt e2444a1679bd6ea2, status open. A statistical range, not company guidance.

## Health Watch, last 12 months

- Item 5.02 Director or officer change: 2, latest 2026-07-24 ([filing](https://www.sec.gov/Archives/edgar/data/893949/000119312526316225/0001193125-26-316225-index.htm))

## Recent filings

- 10-Q · filed 2026-10-29 · [filing](https://www.sec.gov/Archives/edgar/data/893949/000119312526436952/0001193125-26-436952-index.htm)
- 8-K · filed 2026-10-29 · 2.02 Results of Operations and Financial Condition; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/893949/000119312526436932/0001193125-26-436932-index.htm)
- 10-Q · filed 2026-08-04 · [filing](https://www.sec.gov/Archives/edgar/data/893949/000119312526331513/0001193125-26-331513-index.htm)
- 8-K · filed 2026-08-04 · 2.02 Results of Operations and Financial Condition; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/893949/000119312526331488/0001193125-26-331488-index.htm)
- 8-K · filed 2026-07-24 · 5.02 Departure or Election of Directors; Appointment of Officers; 7.01 Regulation FD Disclosure · [filing](https://www.sec.gov/Archives/edgar/data/893949/000119312526316225/0001193125-26-316225-index.htm)
- 8-K · filed 2026-07-15 · 2.02 Results of Operations and Financial Condition; 7.01 Regulation FD Disclosure; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/893949/000119312526304033/0001193125-26-304033-index.htm)

## Sources

- facts: https://data.sec.gov/api/xbrl/companyfacts/CIK0000893949.json
- filings: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=893949

## Cite

POPS4, Edgar & Edgarette: Pediatrix Medical Group, Inc. (MD) company card, from the company's own SEC filings, accessed 2026-11-04, https://www.pops4.com/boards/company/MD. CC BY 4.0. For a figure, add the filing URL under filings or sources.

DOI https://doi.org/10.5281/zenodo.23672509 · catalog https://www.pops4.com/boards/catalog.json · Figures as filed with the SEC. Card text CC BY 4.0, POPS4.

Reporting, not investment advice. No price targets and no trading recommendations.

Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.